ahlam1399
05-31-2015, 12:22 AM
UPDATE 1-Pfizer?s Ibrance drug slows progression of breast cancer
CHICAGO May 30 (Reuters) - A Phase III trial of Pfizer Inc's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/46c9bff4/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=E93v8EGA434:Jg1UUrrJPM4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=E93v8EGA434:Jg1UUrrJPM4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=E93v8EGA434:Jg1UUrrJPM4:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=E93v8EGA434:Jg1UUrrJPM4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=E93v8EGA434:Jg1UUrrJPM4:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/E93v8EGA434
CHICAGO May 30 (Reuters) - A Phase III trial of Pfizer Inc's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/46c9bff4/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=E93v8EGA434:Jg1UUrrJPM4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=E93v8EGA434:Jg1UUrrJPM4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=E93v8EGA434:Jg1UUrrJPM4:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=E93v8EGA434:Jg1UUrrJPM4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=E93v8EGA434:Jg1UUrrJPM4:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/E93v8EGA434